Patents Examined by Sally P. Teng
  • Patent number: 6005072
    Abstract: Isolated DNAs encoding opiorph receptor polypeptides are provided. Recombinant cloning vectors which include these DNA sequences and cells which include these vectors are also provided. Methods for detecting the expression, in a tissue, of mRNA encoding a polypeptide encoded by this DNA are encompassed as well as methods for producing these polypeptides. These isolated polypeptides and antibodies to these polypeptides are also contemplated.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: December 21, 1999
    Assignee: American Cyanamid Company
    Inventors: Cecil Mark Eppler, Bradley A. Ozenberger, Jeffrey D. Hulmes
  • Patent number: 6001621
    Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: December 14, 1999
    Assignees: Genetech, Inc., New England Deaconess (NED) Hospital
    Inventors: Paul J. Godowski, Melanie R. Mark, David T. Scadden
  • Patent number: 5994506
    Abstract: A human adrenergic receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are agonists for the adrenergic receptor polypeptide which may be used therapeutically to stimulate the adrenergic receptor and antagonist inhibitors against such adrenergic receptor polypeptides and their use therapeutically to antagonize the adrenergic receptor. Also disclosed are diagnostic methods for detecting mutations in the polynucleotides of the present invention and for detecting levels of the soluble polypeptides in samples derived from a host.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: November 30, 1999
    Assignee: Human Genome Sciences, Inc.
    Inventors: Daniel R. Soppet, Yi Li, Mark D. Adams
  • Patent number: 5985635
    Abstract: The present invention provides human serine/threonine kinase (HSTK) and polynucleotides which identify and encode HSTK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSTK and a method for producing HSTK. The invention also provides for use of HSTK and agonists, antibodies, or antagonists specifically binding HSTK, in the prevention and treatment of diseases associated with expression of HSTK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSTK for the treatment of diseases associated with the expression of HSTK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSTK.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli, Jennifer L. Hillman
  • Patent number: 5985616
    Abstract: The present invention provides mammalian chimeric NPY Y.sub.5 receptors, nucleic acids and vectors encoding the receptors, methods for making the receptors, fragments or fusion proteins thereof using recombinant DNA methodology or chemical synthesis, and methods for using the receptors in screening systems to identify compounds for the treatment of various diseases.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: November 16, 1999
    Assignee: Schering Corporation
    Inventors: Eric McFee Parker, Catherine Devine Strader, Mark Stephen Rudinski
  • Patent number: 5985600
    Abstract: Nucleic acid molecules comprising a nucleotide sequence encoding a mammalian delta opioid receptor are disclosed. The invention provides recombinant materials for the production of mammalian delta opioid receptors.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: November 16, 1999
    Assignee: The Regents of the University of California
    Inventors: Christopher J. Evans, Duane E. Keith, Jr., Robert H. Edwards
  • Patent number: 5985597
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: May 26, 1993
    Date of Patent: November 16, 1999
    Assignees: Merck Frosst Canada, Inc., Vanerbilt University
    Inventors: Anthony Ford-Hutchinson, Colin Funk, Richard Grygorczyk, Kathleen Metters
  • Patent number: 5981251
    Abstract: A novel protein tyrosine phosphatase is the protein designated PTP 1D. The PTP 1D protein may be produced by recombinant means, for example using a nucleic acid construct encoding the protein as provided herein. Also disclosed is an antibody specific for an epitope of PTP 1D, protein. Methods for identifying compounds which bind to a PTP 1D protein and inhibit or stimulate its enzymatic activity, pharmaceutical compositions comprising PTP 1D, and methods for treating a disease associated with PTP 1D protein using such compositions, are provided.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: November 9, 1999
    Assignee: Max Planck Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Wolfgang Vogel
  • Patent number: 5981246
    Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: November 9, 1999
    Assignee: Amgen Inc.
    Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing
  • Patent number: 5981245
    Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: November 9, 1999
    Assignee: Amgen Inc.
    Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing
  • Patent number: 5981708
    Abstract: The present invention is directed to an autocrine growth factor. In particular, it relates to the production, purification and uses of stem cell proliferation factor (SCPF). In various cell lines, the protein of the invention exists in two forms, a soluble form and a membrane bound form which is detectable on the surface of a small percentage of human bone marrow cells and stimulates the proliferation of these cells. Therefore, SCPF may have a wide range of applications including but not limited to augmenting the growth of hematopoietic stem cells. Further, removal of the protein by an antibody may be useful in controlling tumor cell growth.
    Type: Grant
    Filed: July 8, 1997
    Date of Patent: November 9, 1999
    Assignee: University of Florida
    Inventors: Michael J. P. Lawman, Patricia D. Lawman, Nancy D. Denslow
  • Patent number: 5973114
    Abstract: Growth hormone releasing hormone (GHRH) receptor binding has been characterized using a unique binding assay utilizing iodinated GHRH probes. Photoaffinity GHRH probes have been constructed which allow for photolabeling and characterization of the receptor. In addition, high affinity biotinylated GHRH analogs have been constructed. Solubilization of GHRH-R/GHRH complexes and extraction of specifically bound GHRH using a mild detergent solution, followed by affinity chromotography, leads to a substantially purified GHRH-R isolate. Electrophoretic treatment of the GHRH-R isolate produces GHRH-R of sufficient purity to conduct sequencing of the receptor.
    Type: Grant
    Filed: June 23, 1992
    Date of Patent: October 26, 1999
    Assignees: The University of Virginia Patent Foundation, American Cyanamid Company
    Inventors: Michael Oliver Thorner, Bruce David Gaylinn, John Ronald Zysk, Cecil Mark Eppler
  • Patent number: 5968768
    Abstract: The present invention relates to an isolated nucleic acid molecule having a sequence that encodes a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to a construct containing the nucleic acid molecule and to a host cell comprising same. Further, the invention relates to a method of producing a CD6 ligand.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: October 19, 1999
    Assignees: Duke University, Bristol-Myers Squibb Company
    Inventors: Barton F. Haynes, Alejandro Aruffo, Dhavalkumar Patel, Michael A. Bowen, Hans Marquardt
  • Patent number: 5965392
    Abstract: The present invention provides novel NPY/PYY receptor proteins and nucleic acid sequence encoding them. The invention is directed to the isolation, characterization, and pharmacological use of these receptors and nucleic acids. In particular, this invention provides human and rat NPY/PYY receptors (which we call the NPY Y5 receptor) and nucleic acids. Also provided are recombinant expression constructs useful for transfecting cells and expressing the protein in vitro and in vivo. The invention further provides methods for detecting expression levels of the protein as well as methods for screening for receptor antagonists and agonists to be used for the treatment of obesity or anorexia, respectively.
    Type: Grant
    Filed: April 7, 1997
    Date of Patent: October 12, 1999
    Assignee: Bayer Corporation
    Inventors: Yinghe Hu, Michael L. McCaleb, Brian T. Bloomquist, Jaime R. Flores-Riveros, Linda J. Cornfield
  • Patent number: 5965382
    Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: October 12, 1999
    Assignee: Chiron Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
  • Patent number: 5958709
    Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.
    Type: Grant
    Filed: November 8, 1995
    Date of Patent: September 28, 1999
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
  • Patent number: 5958872
    Abstract: Active Survival Domains in the Insulin-like Growth Factor-I Receptor (IGF-IR) required for transmitting the survival signal in vertebrate cells have been identified. In FL5.12 cells transfected with wild type IGF-I receptors, IGF-I provided protection from IL-3 withdrawal analogous to the protection afforded by expression of Bcl-2. Under the same conditions, IGF-I did not have a significant mitogenic effect on FL5.12 cells expressing IGF-I receptors. An IGF-I receptor with a mutation at the ATP-binding site did not provide protection from apoptosis. However, mutations at tyrosine residue 950 or in the tyrosine cluster (1131, 1135, and 1136) in the kinase domain resulted in receptors that retained survival function. In the C-terminus of the IGF-IR, mutation at tyrosine 1251 and at histidine 1293 and lysine 1294 abolished apoptotic function, whereas mutation of the four serines at 1280-1283 did not affect survival. Surprisingly, receptors truncated at the C-terminus had enhanced anti-apoptotic function.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: September 28, 1999
    Assignees: Apoptosis Technology, Inc., Thomas Jefferson University
    Inventors: Rosemary O'Connor, Renato L. Baserga
  • Patent number: 5958723
    Abstract: A novel human DP prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: September 28, 1999
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Yves Boie, Kathleen Metters, Nicole Sawyer, Deborah M. Slipetz
  • Patent number: 5955308
    Abstract: HEOAD54 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HEOAD54 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infraction; ulcers;astma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourettt's syndrome, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: September 21, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Derk J Bergsma, Wendy S Halsey, Jeffrey L Mooney, Ganesh M Sathe
  • Patent number: 5955592
    Abstract: The present invention relates to PTP-D1, a member of the novel PTP-D subfamily of protein tyrosine phosphatases. The present invention is directed to isolated PTP-D1 protein, nucleic acid constructs encoding for PTP-D1, cells containing the nucleic acid constructs, and methods for production and identification of PTP-D1. Antibodies to PTP-D1 protein and methods for screening molecules which can bind to PTP-D1 protein or inhibit or stimulate the protein-tyrosine phosphatase enzymatic activity of PTP-D1, are also provided.
    Type: Grant
    Filed: April 27, 1994
    Date of Patent: September 21, 1999
    Assignee: Max Planck Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Niels Peter Hundahl M.o slashed.ller, Karin Bach M.o slashed.ller